Fulgent Genetics, which offers genetic testing for over 7,500 conditions, filed on Friday with the SEC to raise up to $50 million in an initial public offering.
The Temple City, CA-based company was founded in 2011 and booked $13 million in sales for the 12 months ended June 30, 2016. It plans to list on the Nasdaq under the symbol FLGT. Credit Suisse, Piper Jaffray and Raymond James are the joint bookrunners on the deal. No pricing terms were disclosed.
